TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17573791

Group type: EXPERIMENTAL
Intervention: Standard meal consumed 6 hours prior to bedtime
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard meal consumed 2 hours prior to bedtime
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Late evening meal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Early evening meal
Number of subjects: 32
Study: 16287956

Group type: EXPERIMENTAL
Intervention: Protein diet
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Unsaturated fat diet
Number of subjects: 164

Group type: COMPARATOR
Intervention: Carbohydrate diet
Number of subjects: 164
Study: 11889297

Group type: EXPERIMENTAL
Intervention: toward‐lateral‐flexion group (infants)
Number of subjects: 168

Group type: COMPARATOR
Intervention: away‐lateral‐flexion group (infants)
Number of subjects: 168

Group type: COMPARATOR
Intervention: away‐turning group (infants)
Number of subjects: 168

Group type: COMPARATOR
Intervention: toward‐turning group (infants)
Number of subjects: 168
Study: 10067011

Group type: EXPERIMENTAL
Intervention: Active management group (induction at 39 weeks, N = 98)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Expectant group (spontaneous labor onset, N = 96)
Number of subjects: 194
Study: 7485045

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with Lovastatin
Number of subjects: 186
Study: 1967920

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 7011597

Group type: EXPERIMENTAL
Intervention: Intravenous LHRH (100 micrograms)
Number of subjects: 4
Study: 31678945

Group type: COMPARATOR
Intervention: Best-practice advice (one session of face-to-face self-management advice delivered by a physiotherapist and up to two optional additional sessions)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Progressive functional exercise (up to six sessions of individual face-to-face physiotherapy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Best-practice advice and Progressive functional exercise
Number of subjects: 48
Study: 28155048

Group type: EXPERIMENTAL
Intervention: Non-specific LBP patients
Number of subjects: 483
Study: 26175279

Group type: EXPERIMENTAL
Intervention: US-guided internal jugular vein (USG) puncture
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Internal jugular vein blindly (IJB)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Subclavian vein blindly (SCB)
Number of subjects: 110
Study: 23260332

Group type: EXPERIMENTAL
Intervention: Memory Training (MT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 112
Study: 21483095

Group type: EXPERIMENTAL
Intervention: 6-month group-based multicomponent cognitive intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 43
Study: 19556517

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 120

Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 120
Study: 18193496

Group type: EXPERIMENTAL
Intervention: efavirenz-containing regimens
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: nonadherent subjects
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: missing at least 1 medication dose ever
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: missing at least 1 medication dose in the past month
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: missing at least 1 medication dose in the past weekend
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: lower quality of life (QOL)
Number of subjects: 715
Study: 15134179

Group type: EXPERIMENTAL
Intervention: Long ZDV treatment duration for mothers (more than 7.5 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Short ZDV treatment duration for mothers (no more than 7.5 weeks)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received short treatment
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Short ZDV treatment duration for infants (3 days) when mothers received short treatment
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received long treatment
Number of subjects: 98
Study: 11402637

Group type: EXPERIMENTAL
Intervention: Heat plus patch (5 mg androgen patch with heat-generating patch)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Patch only (5 mg androgen patch without heat)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No patch (no testosterone patch)
Number of subjects: 6
Study: 9596058

Group type: EXPERIMENTAL
Intervention: Smoking cessation and relapse-prevention program including a 20-minute bedside counseling session, a 12-minute video, self-help materials, and follow-up calls
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Realistic implementation scenarios of the intervention
Number of subjects: 2
Study: 7817156

Group type: EXPERIMENTAL
Intervention: Triclosan in olive oil (0.3%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triclosan in soy oil (0.3%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pure soy oil (no triclosan)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triclosan in sunflower seed oil (0.3%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triclosan in PEG (0.15%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triclosan in GLY (0.15%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 3907331

Group type: EXPERIMENTAL
Intervention: 400 mg bid
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: 600 mg hs
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: 400 mg hs
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: 200 mg bid
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: 200 mg hs
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study: 31600715

Group type: EXPERIMENTAL
Intervention: Tourniquet plus intravenous tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tourniquet plus placebo
Number of subjects: 0
Study: 30577758

Group type: EXPERIMENTAL
Intervention: Lifetime risk (LTR) of maternal death
Number of subjects: 2917

Group type: EXPERIMENTAL
Intervention: Maternal mortality ratio (MMR)
Number of subjects: 2917
Study: 26350752

Group type: EXPERIMENTAL
Intervention: Molecular assays for mutation status at KRAS, NRAS, BRAF, and PIK3CA
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) for pTEN and mismatch repair (MMR) protein expression
Number of subjects: 97
Study: 24951164

Group type: EXPERIMENTAL
Intervention: RT + oral cyclophosphamide (RT+C)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: RT + Tamoxifen (RT+Tam)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: RT
Number of subjects: 1100
Study: 22230599

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS) + Visual foam sclerotherapy (VFS)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Visual foam sclerotherapy (VFS) alone
Number of subjects: 97
Study: 20733262

Group type: EXPERIMENTAL
Intervention: OCP-mediated cement just after filling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OCP-mediated cement aged in MEM30 for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OCP-mediated cement aged in MEM30 for 6 weeks
Number of subjects: 0
Study: 17660457

Group type: EXPERIMENTAL
Intervention: TIVA (propofol‐remifentanil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: BAL (fentanyl‐nitrous oxide‐sevoflurane)
Number of subjects: 50
Study: 17572381

Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focusing on a negative social memory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring the memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thought suppression attempts in everyday life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppression vs. focusing
Number of subjects: 0
Study: 15562899

Group type: EXPERIMENTAL
Intervention: Daily supplementation with lemon-flavored cod liver oil (1 teaspoon per day for children > 1 year; halved for children < 1 year) and a children's multivitamin-mineral supplement containing selenium.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Medical records control group (no supplementation).
Number of subjects: 94
Study: 11123828

Group type: EXPERIMENTAL
Intervention: Penicillin (two or more doses)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Penicillin (one or fewer doses)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Penicillin (one dose)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Penicillin (two doses)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Penicillin (three doses)
Number of subjects: 158
Study: 8761138

Group type: EXPERIMENTAL
Intervention: 20 g/d of PEG 4000 without electrolyte addition
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1330435

Group type: EXPERIMENTAL
Intervention: Alternative strategies for the management of pediatric asthma
Number of subjects: 226
Study: 2862081

Group type: EXPERIMENTAL
Intervention: 0.5 mg prostaglandin E2 (PGE2)
Number of subjects: 293

Group type: COMPARATOR
Intervention: gel only
Number of subjects: 293
Study: 31126577

Group type: EXPERIMENTAL
Intervention: Flexion-Distraction (FD) technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: High-Velocity Low-Back Spinal Manipulation (HVLA-SM)
Number of subjects: 150
Study: 29025631

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months
Number of subjects: 2056

Group type: COMPARATOR
Intervention: No isoniazid preventive therapy (no IPT)
Number of subjects: 2056
Study: 25344466

Group type: EXPERIMENTAL
Intervention: Portable monitoring at home (STDHome)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Portable monitoring in sleep laboratory (PSG_STDLab)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Severe cases diagnosed with portable monitoring
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall diagnostic accuracy of portable monitoring
Number of subjects: 58
Study: 24335920

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 385

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 385
Study: 21969450

Group type: EXPERIMENTAL
Intervention: Endurance exercise (END, n = 10)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES, n = 13)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Endurance exercise (END)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Detraining after END
Number of subjects: 23
Study: 19156015

Group type: EXPERIMENTAL
Intervention: Spherical contact lenses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toric contact lenses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wearing no lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Frequency toric lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acuvue Advance for Astigmatism (thin-zone design)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SofLens toric
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toric lenses (excluding Acuvue Advance for Astigmatism)
Number of subjects: 30
Study: 17451643

Group type: EXPERIMENTAL
Intervention: ABA condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: AAA condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABC condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectancy ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrodermal responses
Number of subjects: 0
Study: 15614241

Group type: EXPERIMENTAL
Intervention: 3 visits per week for 3 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 visits per week for 3 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 visit per week for 3 weeks
Number of subjects: 24
Study: 11309004

Group type: EXPERIMENTAL
Intervention: Leucocyte depleting arterial line filter (Pall LG6)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No arterial line filter
Number of subjects: 60
Study: 9128209

Group type: EXPERIMENTAL
Intervention: oHBP using a validated fully automated oscillometric device (Omron HEM‐705CP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: sHBP using calibrated aneroid devices
Number of subjects: 46
Study: 12369756

Group type: EXPERIMENTAL
Intervention: Intravenous injection of glimepiride (1.0 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glimepiride tablet (1.0 mg)
Number of subjects: 12
Study: 3479527

Group type: EXPERIMENTAL
Intervention: Oxiracetam 800 mg bid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30453597

Group type: EXPERIMENTAL
Intervention: Encapsulated casein and sucrose mixture (active)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control product (non-encapsulated)
Number of subjects: 59
Study: 27843950

Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP paste
Number of subjects: 21

Group type: COMPARATOR
Intervention: 5% sodium fluoride varnish (FV)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP paste and 5% sodium fluoride varnish (CPP-ACP-FV)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 21
Study: 25480348

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day plus alfacalcidol 1 μg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 22546009

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone-artesunate (CDA)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Other artemisinin-based combination therapies (ACT)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: G6PD deficiency
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Both G6PD deficiency and CDA treatment
Number of subjects: 351
Study: 20722560

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comparison of dialysis treatments
Number of subjects: 120
Study: 18222001

Group type: EXPERIMENTAL
Intervention: Conservative ocular therapies and chemothermotherapy (intravenous carboplatin followed by transpupillary thermotherapy) after chemoreduction by 2 cycles of carboplatin and etoposide
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (2 cycles of carboplatin and etoposide) followed by ocular therapy and chemothermotherapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ocular therapy and chemothermotherapy
Number of subjects: 83
Study: 16152837

Group type: EXPERIMENTAL
Intervention: Pifubing Xuedu Pill (PXDP) combined with Diyin Tablet (DYT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diyin Tablet (DYT) alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison of total effective rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison of clinical cured rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toxic and adverse reactions
Number of subjects: 60
Study: 12063530

Group type: EXPERIMENTAL
Intervention: Injected heparin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9987495

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant radiochemotherapy (GITSG trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (Bakkevold trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative radiochemotherapy (EORTC-GITCCG trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regional chemotherapy (historical control trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraoperative or postoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative neoadjuvant radiochemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic and regional chemotherapy
Number of subjects: 0
Study: 7838635

Group type: EXPERIMENTAL
Intervention: Intragastric feeding
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Transpyloric feeding
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Small volume feeding (4 mL/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Large volume feeding (10 mL/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: One-third concentration formula
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Two-thirds concentration formula
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Full concentration formula
Number of subjects: 48
Study: 1978770

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Astemizole 10 mg/d
Number of subjects: 30
Study: 639831

Group type: EXPERIMENTAL
Intervention: Norethindrone (5 to 20 mg single oral doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norethindrone from 2 different manufacturers
Number of subjects: 0
Study: 31363457

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (TCS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-coated sutures (NCS)
Number of subjects: 150
Study: 27862880

Group type: EXPERIMENTAL
Intervention: Supera® stenting after subintimal crossing
Number of subjects: 34
Study: 25854295

Group type: EXPERIMENTAL
Intervention: Emotional social support in the intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instrumental social support in the intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 23281706

Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg·kg(‐1)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Clonidine 4 μg·kg(‐1)
Number of subjects: 87
Study: 22332395

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon 2 in the form of suppositories (genferon and viferon)
Number of subjects: 150
Study: 18804331

Group type: EXPERIMENTAL
Intervention: Face-to-face counseling 40 days postpartum plus telephone counseling calls at 4 and 12 weeks later
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care plus self-help material for each parent
Number of subjects: 0
Study: 17098085

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up (Intensive lifestyle intervention)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Post-intervention follow-up (Control group)
Number of subjects: 522
Study: 15236629

Group type: EXPERIMENTAL
Intervention: 60 mg pseudoephedrine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 48
Study: 11231831

Group type: EXPERIMENTAL
Intervention: Relapse prevention program (2 primary care visits with a depression specialist and 3 telephone visits over 1 year)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Relapse prevention program
Number of subjects: 386

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 386
Study: 9272773

Group type: COMPARATOR
Intervention: CEx (Control Exercise)
Number of subjects: 7

Group type: COMPARATOR
Intervention: HEx (Heat Exercise)
Number of subjects: 7
Study: 8385564

Group type: EXPERIMENTAL
Intervention: Amonafide (1600 mg/m2, 24-hour continuous infusion every 21 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Trimetrexate (150 mg/m2, intravenous over 30 minutes every 2 weeks)
Number of subjects: 72
Study: 3083793

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion, 50 ng per kilogram of body weight per minute during cardiopulmonary bypass (CPB)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (18 patients)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (Prostacyclin and Control)
Number of subjects: 43
Study: 31937267

Group type: EXPERIMENTAL
Intervention: Complex gender-transformative intervention (engaging men for gender equality alongside women's participation in VSLAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (matched for socioeconomic characteristics)
Number of subjects: 0
Study: 29626232

Group type: COMPARATOR
Intervention: 0 g WP (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 g WP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 g WP
Number of subjects: 20
Study: 29871205

Group type: EXPERIMENTAL
Intervention: Nasal cellulose powder
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiological sea water
Number of subjects: 50
Study: 25173357

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (2 mg/kg trimethoprim + sulfamethoxazole daily for 12 months)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (daily for 12 months)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Renal scan at 12 months (Antibiotic group)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Renal scan at 12 months (Placebo group)
Number of subjects: 93
Study: 23516089

Group type: EXPERIMENTAL
Intervention: Trunk exercises based on the Bobath concept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine neurorehabilitation exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 0
Study: 21565423

Group type: EXPERIMENTAL
Intervention: Comprehensive individualized bundling infection control measures
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Regular health care and regular measures for preventing HAIs
Number of subjects: 1874